Experimental CAR T-Cell therapy targets tough lymphoma
NCT ID NCT03590574
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested a new treatment called AUTO4 for people with a type of T-cell lymphoma that had come back or not responded to prior therapy. AUTO4 is a CAR T-cell therapy designed to recognize and attack cancer cells carrying a specific marker called TRBC1. The study aimed to check safety and find the right dose, but it was stopped early after enrolling only 20 participants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- AUTO4 (a CAR T-cell therapy targeting TRBC1)
- What this could lead to
- If successful, this approach could offer a new treatment option for people with certain types of T-cell lymphoma that have not responded to standard therapies.
- What could go wrong
- This was a very early (Phase 1/2) trial with only 20 participants, and it was terminated, so results are limited. CAR T-cell therapies can cause severe side effects like cytokine release syndrome.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANAPLASTIC LARGE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Freeman Hospital, The Newcastle upon Tyne Hospitals NHS Foundation Trust
Newcastle upon Tyne, United Kingdom
-
Manchester Royal Infirmary Hospital
Manchester, United Kingdom
-
Queen Elizabeth University Hospital
Glasgow, United Kingdom
-
University College London Hospitals NHS Foundation Trust
London, United Kingdom
-
Vall d'Hebron Institute of Oncology
Barcelona, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple blood test spot lymphoma earlier?
- New drug cocktail shows promise for tough lymphomas
- Promising combo tackles rare blood cancer in chinese patients
- New drug cocktail aims to tackle rare blood cancer
- New pill shows promise for rare blood cancer in Late-Stage trial
- New drug combo shows promise for rare lymphoma in Real-World study